Welcome to my HP!
I started working at Institution of Advanced Bioscience (IAB), Keio University in October 2018. Great interests of my research are DNA damage, DNA repair and drug resistance in cancer therapy. In these years, I have contributed the clinical development of PARP inhibitors through revealing the additional mechanisms of action named PARP-trapping. Schlafen 11 (SLFN11), the lifework gene for me, is more than curious because SLFN11 greatly increases the anti-tumor activity of various DNA-targeting drugs. Here at IAB, I intensively work on to fully understand the functions of SLFN11 as well as to develop the utility of SLFN11 in the clinic as a predictive biomarker of drug sensitivity.